Diabetes (Type 2)

We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".

Propagermanium is an experimental treatment in Australia. This means it has not been approved by the Therapeutic Goods Administration for treatment of DKD in Australia however it has been licensed for use in Japan since 1994 for the treatment of chronic hepatitis B infection.

The purpose of this trial is to test if propagermanium is safe and effective in treating participants with DKD who are on a daily dose of 300 mg irbesartan when compared to placebo.

This study will determine how safe and effective the drug is by:

  • monitoring symptoms that you may experience while on the study;
  • measuring levels of albuminuria and your kidney function during the course of the study;
  • measuring the levels of propagermanium and irbesartan that enters your blood and urine.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The research study is testing a new treatment for vascular dementia (VaD) and Alzheimer’s disease with cerebrovascular disease. The new treatment is called Sailuotong (SLT). SLT is an extract of three standardised Chinese herbs, Ginseng, Ginkgo and Saffron, all of which are individually permitted for over-the-counter sale in Australia.

The primary objective is to determine the effectiveness of the herbal intervention on cognitive function (the brain functions relating to attention, memory, judgement, reasoning, problem solving etc.), activities of daily living and quality of life, and monitor the safety and effectiveness of SLT.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 1)

We are asking women who are pregnant and have Type 1 Diabetes themselves or have a family member with Type 1 Diabetes who would be a first-degree relative of the baby, i.e. the baby’s father or the baby’s older sibling, to consider participating.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Breast

Denosumab is approved for use in osteoporosis. Laboratory research has identified other potential effects, including possibly slowing or stopping breast cell growth. The BRCA-D trial aims to investigate the effects of denosumab on normal breast tissue in patients with BRCA 1 or 2 mutations and to determine if the drug has potential to prevent breast cancer. Breast tissue will be obtained and evaluated before and after the denosumab injections.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

We are looking for people with Crohn's Disease to participate in a study to determine the safety and effictiveness of a new study medication, guselkumab.

Guselkumab is made in the laboratory and is a fully human monoclonal antibody. An antibody is something that targets and kills foreign objects in the body - in this case, small proteins that are released by cells and affect the behaviour of other cells. This antibody, guselkumab, recognizes and blocks a specific small protein, IL-23, which is important in immune and inflammatory processes.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The main purpose of this study is to track the cognitive, lifestyle and psychological markers of a large group of community-based middle-aged adults (40-65 years inclusive) over five years online, in relation to genetic risk factors that are shown to increase risk of Alzheimer’s disease dementia in older adults.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

Research has shown a relationship between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills. The purpose of this study is to test the effects of Deferiprone on your disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The main aim of this study is to investigate the effectiveness of a new drug (CT 1812) in treating mild to moderate Alzheimer’s disease.

Progression towards Alzheimer’s disease has been proposed to be caused by accumulation of beta amyloid protein in the brain that results in cognitive and functional decline. CT1812 is known to be effective in preventing and displacing the binding of this chemical compound from brain cells. In an earlier Phase 1 study in Australia, CT1812 has also been shown to be safe and well-tolerated in healthy volunteers.

The current study therefore aims to further investigate the effectiveness of this drug, while also evaluate safety and tolerability. It is predicted that long term and stable treatment with CT 1812 may help to improve cognitive function in patients through the course of Alzheimer's disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4